A First-in-human Study of KT502 Administered Subcutaneously to Adult Participants With Rheumatoid Arthritis (RA)

Inclusion Criteria

• •Inclusion:
• •1. 18 to 75 years old
• •2. Diagnosis of adult-onset RA for at least 6 months
• •3. Moderately to severely active RA
• •4. Inadequate treatment response as defined in the protocol
• •5. RF + or ACPA+
• •6. Stable use of traditional DMARDs is permitted
• •7. Willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.
• •Exclusion:
• •1. Functional class IV as defined by the ACR Classification of Functional Status in RA
• •2. Presence of any concomitant autoimmune disease other than RA
• •3. Active infection, history of serious recurrent or chronic infection
• •4. History of progressive multifocal leukoencephalopathy
• •5. Have a diagnosis or history of malignant disease within 5 years or breast cancer diagnosed within the previous 10 years.
• •6. History of or planned organ transplant and/or autologous or allogeneic hematopoietic stem cell transplantation
• •7. Receipt of live vaccine within 4 weeks
• •8. Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months after study
• •9. Women who are pregnant or breastfeeding
• •10. Significant or uncontrolled medical disease that would preclude participant participation